By DM Sullivan
July 2026
July marks a pivotal moment in the global Ehlers-Danlos (EDS) community. As the Ehlers-Danlos Society gathers in Allen, Texas, for its Annual Global Learning Conference (July 24–26, 2026), the event serves as more than just an academic exchange; it marks the ten-year anniversary of the Society’s formal expansion into a global powerhouse for connective tissue research and advocacy.
This year’s theme, "Exploring Comorbidities in EDS & HSD," cuts to the core of the patient experience. For decades, the "invisible" nature of these conditions—immune, neurological, gastrointestinal, and vascular—has been the primary barrier to effective treatment. As we mark a decade of progress, we are forced to confront a sobering reality: while our collective knowledge of the underlying biology of EDS has expanded exponentially, the clinical pathway to accessible, coordinated care remains as obstructed as it was ten years ago.
The Evolution of the EDS Landscape: A Chronological Perspective
To understand where we are, we must look back. Recently, while organizing my home office, I unearthed a relic: the brochure from the 2013 Ehlers-Danlos National Foundation (EDNF) conference. Looking at that document is like peering into a time capsule.
In 2013, I was a young mother with three children, all navigating the labyrinth of a new, bewildering diagnosis. Our pediatrician at the time admitted he had never heard of EDS. Finding the EDNF conference felt like discovering a lifeline. The sponsors of that event—Chronic Pain Partners, The Silver Ring Splint Company, and early research pioneers—were the vanguard of a movement that was just beginning to find its voice.
2013: The Early Warnings
The 2013 agenda featured legendary figures like Dr. Claire Francomano, Dr. Frasier Henderson, and Dr. Pradeep Chopra. A session titled, "What Should We Call Our Syndrome?" led by the late Dr. Rodney Grahame, feels hauntingly relevant today as the community awaits the 2026 update to diagnostic criteria.
Even more striking are the early attempts to address the psychiatric stigma. Dr. Alan Pocinki’s presentation on "Pseudopsychiatric Symptoms in EDS" and Dr. Richard Barnum’s work on "Psychiatric Questions in Pediatric Pain Disorders" were years ahead of their time. They were attempting to combat "medical gaslighting" before the term had even entered the common medical lexicon. Despite their efforts, the tragedy is that psychological misdiagnosis remains one of the most prevalent and damaging hurdles for patients today, a fact backed by recent medical literature.
2016–2026: The Decade of Global Reach
The transition from the National Foundation to the modern Ehlers-Danlos Society marked a shift toward global standardization. We have seen a surge in research funding, international collaboration, and increased awareness among medical students. Yet, for the patient, the "gap" between scientific discovery and bedside application has not closed. We have moved from being "unheard" to being "studied," but we are still waiting to be "treated" in a comprehensive, cohesive manner.
Supporting Data: The Complexity of Comorbidity
The focus of the 2026 conference on comorbidities is not merely a clinical preference; it is a necessity for survival. Research indicates that the morbidity of EDS is rarely caused by the connective tissue fragility alone; it is the secondary, multisystem failures that disable patients.
- Neurological Impact: The intersection of dysautonomia (POTS) and structural instability often leads to debilitating chronic pain and fatigue.
- Gastrointestinal Dysfunction: Many EDS patients suffer from gastroparesis or dysmotility, which are frequently dismissed as psychosomatic.
- The Diagnostic Delay: Studies consistently show that the average patient wait-time for a definitive diagnosis is still measured in years, often involving multiple specialists who do not communicate with one another.
The film Complicated, which highlights the journey of patients like Karen Richards, underscores these realities. I remember meeting Karen in 2013 when she was a vibrant 12-year-old. Her boldness—famously leaving Dr. Rodney Grahame speechless by telling him, "My doctors hear me, but they don’t listen"—is the anthem of our community. That gap between "hearing" and "listening" is the core issue of modern medicine regarding rare diseases.
Official Responses and the Need for Systemic Reform
While the Ehlers-Danlos Society has been instrumental in producing updated clinical guidelines, the onus of implementation falls on regional healthcare systems. The professional consensus, as expressed by researchers at recent international symposia, is that "multidisciplinary clinics" are the gold standard. However, insurance structures, reimbursement models, and medical education are lagging.
The medical community is finally acknowledging the validity of these comorbidities. We are seeing more industry investment in treatments for connective tissue disorders. But as an advocate, I have found that knowledge is only the first step. True medical progress requires:
- Standardized Referral Pathways: Reducing the "ping-pong" effect between cardiology, neurology, and gastroenterology.
- Educational Integration: Ensuring that medical schools teach EDS as a systemic condition, not just a orthopedic curiosity.
- Coordination Models: Moving away from the "siloed" specialist approach to a "case manager" model that treats the patient as a whole.
Implications: Where Do We Go From Here?
As I prepare for the trip to Texas, my emotions are mixed. There is pride in how far we have come—the research is robust, the community is organized, and our voices are louder than ever. But there is also a lingering grief for the families, including my own, who continue to struggle despite our increased knowledge.
The struggle to find informed care remains an expensive, exhausting, and often lonely endeavor. The emergence of long-COVID and its overlap with EDS-like symptoms has only added a new layer of complexity to the lives of patients who were already fighting for recognition.
Looking Toward the Next Decade
When we look at the brochures from 2013, we see a community in its infancy, fighting for the right to be diagnosed. In 2026, we are a global movement fighting for the right to be treated effectively. The shift in focus to comorbidities is a sign of maturity in our advocacy. We are no longer just asking "What is this?"; we are asking "How do we live with this?"
I will be bringing a new brochure home from Texas. I will tuck it away in my office, alongside the one from 2013. My hope, as I look forward to 2036, is that when I open that drawer again, the struggle for basic, coordinated, and compassionate care will have transitioned from a daily battle into a historical footnote.
We have the research. We have the passion. Now, we need the systemic commitment to translate that into tangible health outcomes. The next decade must be defined not by how much more we learn, but by how much better we care.
DM Sullivan is a patient, caregiver, and the producer of the documentary ‘Complicated.’ She serves as the Founder and Executive Director of Elevate Rare, continuing to advocate for those navigating the intersection of chronic pain and complex, multisystem disease.
